Clinical trials: Pioglitazone
Lung Cancer, Endobronchial Dysplasia
Pioglitazone for Lung Cancer Chemoprevention
This is a chemoprevention trial evaluating the diabetic agent pioglitazone. Non-diabetic subjects at risk for lung cancer (based on smoking history, lung function testing, and atypical cells in a sputum sample) receive either…
- Trial name
- NCT00780234
- Testing
- fluorescence bronchoscopy, quantitative high resolution CT scan
- Where
- 2 sites in United States
- Volunteers
- 92 people
- Sponsor
- VA Office of Research and Development
Type 2 Diabetes
Safety and Efficacy Study to Compare Vildagliptin to Pioglitazone as Adding on Metformin in Type 2 Diabetes
The purpose of this study is to compare the effect of 16 weeks treatment with vildagliptin to pioglitazone as add-on the therapy to metformin in patients with type 2 diabetes inadequately controlled with metformin monotherapy.
- Trial name
- NCT01882907
- Testing
- vildagliptin, Pioglitazone
- Where
- 15 sites in South Korea
- Volunteers
- 287 people
- Sponsor
- Pusan National University Hospital
Type 2 Diabetes Mellitus
A Study Comparing Insulin Peglispro With Insulin Glargine as Basal Insulin Treatment
The purpose of this study is to compare insulin peglispro (LY2605541) to insulin glargine in Asian insulin naïve participants who have been treated with oral anti hyperglycemia medications.
- Trial name
- NCT01894568
- Testing
- Insulin Peglispro, Insulin Glargine, Oral Antihyperglycemic Medications (OAMs)
- Where
- 31 sites in Japan, South Korea and 1 more
- Volunteers
- 388 people
- Sponsor
- Eli Lilly and Company
Type 2 Diabetes Mellitus
Pioglitazone Tablets Special Drug Use Surveillance "Combined Use of Insulin Products / Long-term Treatment"
The purpose of this study is to investigate the safety and efficacy of long-term treatment with pioglitazone (Actos Tablets) in the routine clinical setting in combination with an insulin product in patients with type 2 diabetes…
- Trial name
- NCT02068508
- Testing
- Pioglitazone
- Volunteers
- 1,067 people
- Sponsor
- Takeda
Type 2 Diabetes Mellitus
Pioglitazone Special Drug Use Surveillance "Metabolic Syndrome in Patients With Type 2 Diabetes Mellitus"
The purpose of this survey is to determine the onset of new cerebral and cardiovascular events and changes in metabolic syndrome parameters in patients with type 2 diabetes mellitus on long-term pioglitazone (Actos Tablets)…
- Trial name
- NCT02002975
- Testing
- Pioglitazone
- Volunteers
- 18,223 people
- Sponsor
- Takeda
Type 2 Diabetes Mellitus
Pioglitazone Tablets Specified Drug-use Survey <Survey on Glycemic Control in Type 2 Diabetic Patients With a History of Cerebral Infarction>
The purpose of this survey is to evaluate the effects on glycemic control and to evaluate the safety of long-term use of pioglitazone tablets (Actos Tablets) in type 2 diabetic patients with inadequate glycemic control and a…
- Trial name
- NCT02181842
- Testing
- Pioglitazone
- Volunteers
- 246 people
- Sponsor
- Takeda
Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive
Pioglitazone and Tyrosine Kinase Inhibitor in Treating Patients With Relapsed Chronic Myeloid Leukemia
This phase II trial studies how well pioglitazone hydrochloride and tyrosine kinase inhibitor (TKI) therapy works in treating patients with chronic myeloid leukemia (CML) that has come back after a period of improvement…
- Trial name
- NCT02730195
- Testing
- Pioglitazone, Tyrosine Kinase Inhibitor (TKI)
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- Emory University
HIV-1 and Hepatitis C Co-Infection
Pioglitazone Before Peginterferon and Ribavirin for Hepatitis C Infection in HIV/HCV-Coinfected Patients With Insulin Resistance
Insulin resistance is common in people coinfected with HIV and Hepatitis C virus (HCV) and is associated with poor responses to treatment for HCV. Pioglitazone is an FDA-approved medication for the treatment of type 2 diabetes.
- Trial name
- NCT00665353
- Testing
- pioglitazone, peginterferon, ribavirin
- Where
- 8 sites in United States
- Volunteers
- 19 people
- Sponsor
- Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections
Type II Diabetes Mellitus
Efficacy of Pioglitazone in Participants With Inadequately Controlled Type 2 Diabetes Mellitus Treated With Stable Triple Oral Therapy
The purpose of this study is to evaluate the efficacy of pioglitazone 30 mg on glycemic control when used in participants with inadequately controlled type 2 diabetes mellitus treated with stable combinations of metformin and…
- Trial name
- ADD (NCT01972724)
- Testing
- Pioglitazone, Metformin, Sulfonylurea
- Where
- 9 sites in South Korea
- Volunteers
- 114 people
- Sponsor
- Takeda
Nonalcoholic Steatohepatitis
Prevalence of Non-alcoholic Fatty Liver Disease (NAFLD) in Hispanics With Diabetes Mellitus Type 2 (T2DM) and Role of Treatment
Nonalcoholic fatty liver disease (NAFLD) is a chronic liver condition frequently associated with type 2 diabetes (T2DM) and characterized by insulin resistance and hepatic fat accumulation.
- Trial name
- VA NASH (NCT01002547)
- Testing
- pioglitazone, Vitamin E
- Where
- 2 sites in United States
- Volunteers
- 105 people
- Sponsor
- VA Office of Research and Development
Type 2 Diabetes Mellitus
A Dose-Range Finding Study in Participants With Type 2 Diabetes (MK-3102-006)
The purpose of this study is to assess the hypothesis that treatment with study medication (omarigliptin; MK-3102) provides greater reduction in A1C Hemoglobin (a marker of diabetic severity) compared with placebo, after 12 weeks…
- Trial name
- NCT01217073
- Testing
- Omarigliptin, Pioglitazone, Metformin
- Volunteers
- 685 people
- Sponsor
- Merck Sharp & Dohme LLC
Non-alcoholic Fatty Liver Disease
Study of Changes in Hepatic Fat Following Administration of MK-4074 and Pioglitazone Hydrochloride (MK-4074-008)
This study will evaluate changes in liver fat content following multiple oral doses of MK-4074 and Pioglitazone Hydrochloride in adult males and females with fatty liver disease.
- Trial name
- NCT01431521
- Testing
- MK-4074 200 mg, Pioglitazone hydrochloride 30 mg
- Volunteers
- 31 people
- Sponsor
- Merck Sharp & Dohme LLC
Diabetes
Pioglitazone and Serum Asymmetric Dimethylarginine (ADMA) in Patients With Diabetes
SPECIFIC AIMS 1. To determine whether pioglitazone will reduce levels of asymmetric dimethylarginine(ADMA) in patients with diabetes. 2. To determine whether nitric oxide(NOx) products are increased with pioglitazone treatment.
- Trial name
- NCT00770367
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- Medical University of South Carolina
Obesity, Overweight With Indications for Weight Loss
Optimizing Body Composition for Function in Older Adults
The purpose of this pilot study is to compare two strategies intended to improve the health of overweight older adults by improving body composition.
- Trial name
- NCT00315146
- Testing
- Pioglitazone, Resistance exercise training to maximize muscle power, Hypocaloric diet
- Where
- United States
- Volunteers
- 88 people, healthy volunteers welcome
- Sponsor
- Wake Forest University Health Sciences
Type II Diabetes, Nonalcoholic Fatty Liver
Fatty Liver Study in Patients With Type II Diabetes
The primary objective of this trial is to measure changes in hepatic lipid content using three common alternative therapeutic strategies to improve glycemic control in patients with type 2 diabetes who are not controlled with…
- Trial name
- NCT02365233
- Testing
- DPP4 inhibitor, Pioglitazone, Lantus insulin
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- The University of Texas Medical Branch, Galveston
Cocaine Use Disorder, Alcohol Use Disorder
PPARγ Agonist Treatment for Cocaine Dependence
The purpose of this research study is to determine whether a medication called pioglitazone (trade name Actos) can reduce behavioral problems associated with cocaine use, improve brain structural changes associated with cocaine…
- Trial name
- NCT02774343
- Testing
- Pioglitazone, Therapy, Contingency Management
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- The University of Texas Health Science Center, Houston
Liver Diseases
Pioglitazone vs Vitamin E vs Placebo for Treatment of Non-Diabetic Patients With Nonalcoholic Steatohepatitis (PIVENS)
The purpose of this study is to determine if therapy with pioglitazone or vitamin E will lead to an improvement in liver histology in non-diabetic adult patients with non-alcoholic steatohepatitis (NASH).
- Trial name
- PIVENS (NCT00063622)
- Testing
- Pioglitazone, Vitamin E
- Where
- 8 sites in United States
- Volunteers
- 247 people
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Diabetes, Bladder Cancer
Cohort Study of Pioglitazone and Bladder Cancer in Patients With Type II Diabetes
To assess the potential association between pioglitazone and bladder cancer compared with non-pioglitazone users among patients with type 2 diabetes mellitus.
- Trial name
- NCT01637935
- Testing
- Pioglitazone
- Volunteers
- 193,099 people
- Sponsor
- Takeda
Diabetes Mellitus, Type 2, Cancer
Cohort Study of Pioglitazone and Cancer Incidence in Participants With Diabetes Mellitus.
The purpose of this study was to evaluate whether treatment with pioglitazone is associated with risk of incident cancer at the 10 most common sites in a cohort of participants with recognized diabetes.
- Trial name
- NCT02958956
- Testing
- Pioglitazone
- Volunteers
- 236,507 people
- Sponsor
- Takeda
Cystic Fibrosis
Safety and Efficacy of Pioglitazone as an Anti-inflammatory for the Treatment of Cystic Fibrosis (CF) Lung Disease
Study Hypothesis: Pioglitazone may decrease inflammation in cystic fibrosis lung disease. Primary outcomes: Markers of inflammation (neutrophils, elastase, cytokines and bacteria)will be measured in induced sputum specimens…
- Trial name
- NCT00322868
- Testing
- pioglitazone
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- University Hospitals Cleveland Medical Center